Alzheimer’s Disease Diagnostics and Treatment Market Size, Share, and Growth Forecast, 2025 - 2032

The global Alzheimer’s disease diagnostics and treatment market size is projected to rise from US$ 7.72 Bn in 2025 to US$ 14.14 Bn by 2032. It is anticipated to witness a CAGR of 9.0% during the forecast period from 2025 to 2032. Surge in dementia cases across the globe is estimated to boost the advancement in diagnostics and treatment for Alzheimer's disease in the forthcoming years.

The World Health Organization (WHO) stated in 2023 that around 10 million instances of dementia are recorded each year, affecting 55 million people globally. Alzheimer's is the most prevalent kind of dementia, accounting for 60% to 70% of cases.

Government and non-government organizations are investing heavily in diagnoses and treatments due to the increasing incidence of Alzheimer's disease worldwide, which might increase the demand for Alzheimer's disease treatments.

Key Industry Highlights

• Leading Region: North America, estimated to witness a CAGR of 7.2% through 2032, supported by a surge in clinical trials, advanced healthcare infrastructure, and ongoing R&D in Alzheimer’s treatments.
• Fastest-growing Region: Europe, fueled by increased awareness and early diagnosis campaigns, leading to more patients seeking evaluation and treatment at earlier disease stages.
• Dominant Solution Type: Advancements in diagnostic technology are expected to drive Alzheimer's diagnostic tests to a 65% global market share in 2025, reflecting growing demand for reliable solutions.
• Leading Sales Channel: Institutional sales are set to dominate the Alzheimer's disease market in 2025 with a 68% share, driven by the critical role of hospitals and care facilities in managing the disease's complex needs.

Driver - Neuroimaging Technologies Enable Earlier and More Accurate Diagnosis

Neuroimaging technologies, such as PET scans with amyloid tracers, are improving the accuracy of diagnostics and driving market growth. Companies are expanding their product offerings and launching new products due to ongoing research in the healthcare industry.

The Alzheimer’s disease diagnostics and treatment market is expected to grow in tandem with various healthcare initiatives, such as clinical trials and development in healthcare technology, during the forecast period.

• In February 2023, Athira Pharmaceuticals announced its plans for clinical trials in 2023, focusing on the development of therapeutic drugs for treating Alzheimer's disease.
• In January 2023, Cyclo Therapeutics, Inc., enrolled the first patient in its Phase IIb study of Trappsol Cyclo for the treatment of early Alzheimer's disease.

The development of improved Alzheimer's treatments aims to target disrupted lipid pathways while reducing amyloid beta and tau proteins, further driving the growth of the Alzheimer's disease diagnostics and therapeutics market.

Restraint - High Medical Expenses Limit the Adoption of Prevalent Therapeutics

The high cost of diagnosing Alzheimer's disease poses a significant barrier to growth, as it incurs substantial economic and societal expenses for the healthcare system, individuals, families, and careers. Studies indicate that both the direct and indirect costs associated with Alzheimer’s disease-related healthcare are high, including expenses related to post-mortem brain tissue assessments using PET and CSF biomarkers, as well as innovative clinical criteria.

The cost of an accurate dementia diagnosis is calculated by dividing the total expenses of all investigative procedures by the number of confirmed diagnoses, utilizing unit costs for various diagnostic components. Additionally, the global prevalence of Alzheimer's disease is projected to rise dramatically due to the aging population, which will increase costs and hinder the growth of the Alzheimer's diagnostics and therapeutics market during the forecast period.

Opportunity - Integration of AI Presents Promising Prospects for Innovation in the Healthcare Industry

AI is transforming Alzheimer's research by analyzing MRI images and blood samples from patients worldwide. Convolutional neural networks, vision transformers, and federated learning are some of the cutting-edge methods being used by healthcare institutions to forecast the course of diseases and spot early warning indicators.

• The Artificial Intelligence for Alzheimer's Disease Consortium (AI for AD), funded by the National Institutes of Health (NIH) with a US$18 Mn grant, spans 12 research sites across the U.S., with USC as the lead site.

AI's role in personalized treatment and drug discovery is promising, as it can help determine the most effective treatments for individuals based on their unique genetic and clinical profiles. The consortium is now collaborating with pharmaceutical companies such as Biogen to develop innovative imaging techniques that make it easier to track Alzheimer's progression and test new drugs. The future of AI in Alzheimer's research is promising, with multimodal AI combining various types of medical data to improve diagnosis and treatment predictions.

Solution Insights

Improvements in diagnostic technology are expected to enhance the accuracy and reliability of Alzheimer's diagnostic tests, leading to a market share of 65% for these diagnostics in 2025. This rise reflects an increasing demand for trustworthy diagnostic solutions. Companies such as Roche and Biogen are investing in innovative diagnostic methods, including cerebrospinal fluid biomarker tests, blood-based biomarker tests, computerized cognitive assessments, and brain imaging techniques. These advancements aim to improve early detection and treatment planning, thereby accelerating market expansion.

In addition, the senior population and the pressing need for efficient therapies that address the illness's underlying causes are driving the growth of the global Alzheimer's disease research sector, with disease-modifying treatments predicted to account for 35% of the market share in 2025. Eli Lilly, for instance, is expanding its production capabilities with a US$1.8 Bn investment in Ireland to meet the growing demand for its Alzheimer's drug. The rising prevalence of the disease, along with advancements in treatment options, propels the market growth in the forthcoming period.

Sales Channel Insights

Institutional sales are projected to dominate the Alzheimer's disease market in 2025, holding a market share of 68%. Hospitals, clinics, and long-term care facilities play a critical role in managing Alzheimer's due to the disease's complexity, requiring specialized diagnostic and therapeutic solutions.

The demand for institutional care is rising due to the increasing number of Alzheimer's patients, expected to reach 7.2 million in the U.S. by 2025. Healthcare providers are investing in advanced diagnostic tools and therapeutics, such as Eli Lilly’s donanemab and Biogen’s Leqembi, to enhance patient care.

Retail sales, accounting for 32% of the market in 2025, are experiencing rapid growth due to increased awareness and proactive health management. Consumers are turning to cognitive aids, caregiver support products, and digital health solutions for early intervention. Companies such as Neurotrack and Cogstate are expanding digital cognitive assessment tools, enabling early detection and at-home monitoring, driving further market expansion.

North America Alzheimer’s Disease Diagnostics and Treatment Market Trends - Increasing Prevalence of Clinical Trials in North America Presents Novel Diagnostics

North America is estimated to hold 38% of the market share in 2025, due to its high incidence, robust healthcare infrastructure, and extensive research. The patient population in the U.S. and Canada contributes to the disease's prevalence. Researchers are expected to increase the clinical trials involving these patients to enhance research and development on drugs and therapies.

For instance, in 2024, market players conducted 48% of clinical trials exclusively in North America, 33% outside North America, and 20% across both North American and international locations. Overall, North America is expected to host approximately 67% of all clinical studies listed in the National Institutes of Health (NIH) database.

The region's advanced healthcare infrastructure, innovative solutions, access to advanced neuroimaging technologies, and well-equipped research facilities further contribute to its dominance in the market.

Europe Alzheimer’s Disease Diagnostics and Treatment Market Trends - Healthcare Initiatives at the Forefront for Surge in Alzheimer’s Disease Diagnostics

Alzheimer's disease is a growing problem in Europe, with around seven million people living with the disease, and its number is set to double by 2050. Healthcare initiatives such as the new IHI project AD-RIDDLE aim to revolutionize the detection, diagnosis, prevention, and treatment of Alzheimer's disease by delivering a modular and customizable toolbox platform.

Such medical platforms are envisioned to offer a digital community engagement portal, self-guided assessment tools, pathways for referral to appropriate healthcare services, screening and diagnostic tools, and a decision support toolkit for healthcare providers. The modular toolbox is set to be tested in different healthcare settings across six countries in Europe, such as the U.K. and Germany, and data from AD-RIDDLE will be hosted by the European Platform for Neurodegenerative Diseases (EPND).

European players are collaborating with various sectors, universities, healthcare providers, and regulatory bodies to develop a novel approach to Alzheimer's disease prevention, diagnosis, and management.

Asia Pacific Alzheimer’s Disease Diagnostics and Treatment Market Trends - Healthcare Systems in Asia Pacific Under Pressure as Dementia Cases Surge

Asia Pacific is experiencing a transition from infectious diseases to chronic diseases, that impacts the balance between hospitals, public health, and primary care services. A significant concern is the rising prevalence of dementia, largely driven by lifestyle changes in the geriatric population. Emerging countries such as India and China are witnessing the most notable increases in dementia cases.

By 2050, it is projected that managing over 70 million people with dementia in the Asia Pacific is projected to place immense pressure on family, community, and healthcare resources. Supporting individuals with dementia requires a multidimensional approach that addresses their medical, cognitive, psychological, environmental, cultural, and social needs. The Lancet Commission has highlighted biological and lifestyle risk factors for dementia, such as social determinants, neuroimaging data, alcohol, smoking, and food, as contributing to rising dementia cases and the erosion of traditional community structures in the Asia Pacific.

The global Alzheimer’s disease diagnostics and treatment market is highly competitive, with manufacturers investing heavily in research and development to develop new diagnostic tools and treatments for Alzheimer's disease. They are diversifying their product offerings and expanding their offerings through acquisitions, collaborations, and clinical trials.

Prominent entities in the Alzheimer's disease diagnostics and treatment sector, such as Biogen, Eli Lilly, and Pfizer, use comprehensive strategies to maintain and augment their market dominance. They focus on developing disease-modifying therapies, such as Aducanumab, which targets fundamental etiological factors, and forming strategic alliances with healthcare providers and research institutions. Market players also focus on providing all-encompassing diagnostic solutions, such as digital health solutions, to enhance early detection and monitoring capabilities.

Key Industry Developments

• In January 2025, C2N Diagnostics and The Michael J. Fox Foundation for Parkinson's Research collaborated to study the link between neurodegenerative conditions such as Alzheimer's and NSD, using C2N's PrecivityAD2™ blood test for brain amyloid plaque detection.
• In December 2024, the UK Quantum Biomedical Sensing Research (Q-BIOMED) hub, led by UCL and the University of Cambridge, launched a US$29.76 Mn initiative to use quantum technology for early disease diagnosis and treatment, as part of the U.K. Government's National Quantum Technologies Programme.
• In November 2024, Royal Philips and Icometrix partnered to develop an AI-driven solution for MRI brain scans, aiming to optimize diagnosis and treatment monitoring for neurological conditions, including Alzheimer's and MS.
• In September 2024, India's Drugs Controller General approved indigenous in-vitro biomarkers for early detection of critical diseases including Alzheimer's and cancer, a collaboration between Agape Diagnostics Ltd. and Fujirebio Holdings Inc.
• In August 2024, Genova Diagnostics introduced the Alzheimer's Assessment, a non-invasive blood test using the p-Tau217 biomarker for early detection and management of Alzheimer's disease.